introduction
Breast cancer is a heterogeneous disease, encompassing at least three major subtypes: the hormone receptor (HR) positive, the human epidermal growth factor receptor 2 (HER2) positive and the triple-negative (TN) subtype [1, 2] . Adjuvant treatments are selected according to the molecular subtype of breast cancer; however, in spite of more effective therapies, 20% to 30% of the patients with early breast cancer will eventually relapse [3, 4] . At the time of relapse, treatment decisions are still based on the biological features of primary tumor, although a growing body of evidence indicates a lack of concordance in receptor status between primary and recurrent tumors in up to 40% of the cases [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . We have previously reported a discordance of 21% for HR expression and of 16% for HER2 status in a retrospective analysis including 75 patients [15] .
Nowadays, tissue confirmation of recurrent breast cancer is suggested by international guidelines whenever possible [16] . The impact of this approach on patient management and outcome is not yet clear, even though preliminary data indicate that the molecular characterization of recurrent breast cancer may induce clinicians to modify the treatment choice in ∼14% of the cases [8, [17] [18] [19] and that a change in the receptor status is associated with poorer survival [7, 20, 21] .
Aim of this study is to assess the discordance rate in HR and HER2 expression from primary breast tumor to matched recurrent disease, and to evaluate the prognostic impact of the change in tumor phenotype in a single-Institution series.
materials and methods case selection
Consecutive cases of patients who underwent biopsy or surgical resection of suspected recurrent breast cancer at our Institution between January 1997 and December 2007 were retrieved from the archive of the Pathology Division. Since 2007, we prospectively maintained a dedicated database including all breast cancer patients treated at our Institution with biopsy or resection of suspected metastatic lesions.
The cases of bilateral breast cancer with discordant histology/receptor status as well as the cases where metastatic disease was documented by fine-needle aspiration (FNA) only were excluded.
Patient characteristics including stage at diagnosis, adjuvant therapies, site of relapse, site of biopsy, and treatments for advanced disease were recorded.
pathology
All the pathology assessments were performed at the Pathology Division of our Institution by a dedicated breast pathologist (G.F.). When breast cancer was diagnosed elsewhere, unstained slides were retrieved by referring Institution and de novo analyzed in our Pathology Division.
The same assays and standardized methodology were applied to each sample. Those primary samples initially tested with different assays and/or procedures were retested according to procedures used for testing the matched biopsy. All paired samples showing discordance in at least one of the three receptors (ER, PgR or HER2) were simultaneously retested and reviewed. In case of HER2 discordance as assessed by IHC(0/1+ versus 3+ score), a FISH analysis on both samples was performed for confirmation. In case of disagreement between IHC and FISH, the HER2 status was defined according to the FISH results.
IHC staining, FISH and scores
Tumor specimens were fixed in 10% neutral-buffered formalin for 20-28 h before processing and embedding. The following monoclonal antibodies were used: ER (Ventana Medical Systems, clone SP1, prediluted, HIAR); PgR (Ventana, clone 1E2, prediluted, HIAR); Ki67 (DAKO, clone Ki67-MIB-1, 1:200 dilution, HIAR); HER2 (Ventana, clone 4B5, prediluted, HIAR).
The cut-off for ER positivity and PgR positivity was IHC staining in ≥10% of the cells. Cases were classified as HR positive in case of ER and/or PgR positivity and as HR negative in case of both ER negativity and PgR negativity.
The scoring of HER2 by IHC was: 0 (no membrane staining); 1+ (weak and incomplete membrane staining), 2+ (strong, complete membrane staining in ≤30% of tumor cells or weak/moderate heterogeneous complete membrane staining in ≥10% of tumor cells), or 3+ (strong, complete, homogeneous membrane staining in >30% of tumor cells). In the case of IHC HER2 score 2+, a confirmatory FISH test was run. FISH analysis was performed using the PathVysion HER-2 DNA Probe Kit (Vysis Inc., Downers Grove, IL). Hybridization signals were scored in at least 60 intact non-overlapping nuclei. The results were classified in: amplified (HER2/ CEP17 ≥ 2) and non-amplified (HER2/CEP17 <2). Overall, samples were considered HER2 positive in the case of IHC 3+ score and/or FISH amplified, and negative in the case of IHC 0/1+ and/or non-FISH amplified.
statistical analysis
All data were presented descriptively as medians, means or proportions. The association between categorical variables and discordance was determined using the χ 2 test. Continuous variables were compared by using Student's t-test for paired data. Post-recurrence survival (PRS) was calculated from the date of relapse to the date of death or last follow-up. Overall survival (OS) was calculated from the time of primary breast cancer diagnosis to the date of death or last follow-up. Survival curves were estimated with the Kaplan-Meier method and the log-rank test was used to test for differences between groups. Hazard ratios and their CIs were calculated by using the Cox regression model. Results were considered statistically significant if P-value < 0.05. Data were analyzed using STATA version 9.
results

patient characteristics
A hundred and sixty-six breast cancer patients who underwent sampling of suspected recurrent breast cancer were retrieved: 9 cases of bilateral breast cancer and 18 cases with FNA only were excluded leaving 139 patients eligible. In 20 cases, the biopsy of the suspected metastatic lesion resulted in a second malignancy diagnosis (lung, n = 11; renal, n = 2; lymphoma n = 2; gastro-intestinal, n = 2; other, n = 3), whereas a relapsed breast cancer was confirmed in 119 patients. Sites of biopsied recurrences were distant metastases in 75 cases (63%) and locoregional soft tissues or lymph-nodes in 44 cases (37%); in 22 of these 44 patients, synchronous distant metastases were also present but locoregional recurrences were sampled to minimize the invasiveness of the bioptic procedure ( Figure 1 ).
The mean time between the primary diagnosis and the recurrence biopsy was 68 months (range 0.5-238 months).
The characteristics of the patients with matched primary and recurrent breast cancer are summarized in Table 1 .
discordance in single-receptor measurement
The rates of discordance in single-receptor measurements are summarized in Table 2 . Overall, a change in HER2-status was observed in 14 cases (11.8%). In detail, among the 21 patients with HER2-positive primary tumors, 4 (19%) changed to HER2 negative, whereas 17 (81%) maintained HER2 positivity. Ten out of the 98 patients (10.2%) with HER2-negative primary tumor acquired HER2 positivity at relapse.
A discordance in HR status was observed in 15 cases (12.6%), with the loss and gain of HR positivity in 12 out of 95 patients (12.7%) and 3 out of 24 patients (12.5%), respectively. Similar results were observed for ER-status changes. The original articles Annals of Oncology highest rate of discordance was observed for PgR (39%), with PgR loss as the main change.
Quantitative absolute changes in ER, PgR and Ki67 are reported as waterfall plots in Figure 2 . A significant increase in mean Ki67 from primary tumor (27%, range 1-100%) to recurrence (34%, range 4-95%) was observed (P = 0.01).
No correlation between discordance (HR and HER2) and biopsy site (locoregional versus distant) was observed.
The 10 patients who converted to HER2 positivity subsequently received trastuzumab. Six patients received multiple line of anti-HER2 therapy (lapatinib, T-DM1, neratinib). Four patients are still on anti-HER2 treatment at the time of this report.
The three patients who changed from HR negative to HR positive were subsequently treated with endocrine therapy.
prognostic impact of single-receptor discordance
No significant difference in prognosis was observed according to the overall HER2-discordance. Conversely, the patients with a loss in HER2 expression experienced a significantly worse PRS (median 16 versus 88 months, P = 0.008) and a trend to a worse OS (median 40 versus 108 months, P = 0.06) when compared with patients who maintained the HER2 positivity. Notably, none of these patients has been denied anti-HER2 therapy because of the loss of HER2 receptor.
The ER-discordant cases, when compared with the ERconcordant cases, showed a poorer clinical outcome (median 27 versus 50 months, P = 0.01 and median 59 versus 112 months, P = 0.0005, for PRS and OS, respectively). Median OS was 59 months for the patients who changed from ER positive to ER negative and 130 months for the concordant ER-positive group (P = 0.001), without significant difference in terms of PRS (P = 0.07). Discordance in PgR status did not correlate with PRS or OS (P = 0.9 and P = 0.5, respectively). No impact on survival was observed for PgR loss (P = 0.8 and P = 0.1 for PRS and OS, respectively).
Overall, a change in HR status resulted in a worse PRS (median 28 versus 50 months, P = 0.002) and OS (median 59 versus 119 months, P < 0.0001). Those patients who changed from HR positive to HR negative experienced both worse PRS (median 27 versus 54 months, P = 0.01) and OS (median 59 versus 130 months, P = 0.0002) when compared with those who maintained HR positivity.
Survival curves for HER2 loss and HR loss are shown in Figure 3 . 
Annals of Oncology original articles
No significant impact on outcome was observed in the case of gain of ER, PgR, HR or HER2 expression, when compared with the respective concordant negative groups.
discordance in tumor phenotype
According to the expression of HR and HER2, patients were classified into four subtypes: HR positive/HER2 negative, HR positive/HER2 positive, HR negative/HER2 positive and HR negative/HER2 negative (TN). The same tumor phenotype was maintained in 92 of 119 patients (77.3%), while 27 patients (22.7%) had a change in tumor phenotype during progression: a switch to a TN status was observed in 9 cases, whereas 18 discordant patients showed either HR or HER2 positivity at recurrence (Table 2) .
prognostic impact of tumor phenotype discordance
Patients who maintained their tumor phenotype unchanged showed a significant better outcome when compared with discordant cases, both in terms of PRS (median 51 versus 29 months, P = 0.006) and OS (median 119.2. versus 68 months, P = 0.002).
Among the discordant cases, the patients whose tumor phenotype turned into TN had the worst PRS (median 27 versus 51 months, hazard ratio 4.35; 95% CI 2.07-9.15, P < 0.0001) and OS (median 59.3 versus 119.2 months, hazard ratio 2.70; 95% CI 1.31-5.55, P = 0.007), when compared with the concordant group.
Survival curves according to phenotype discordance are reported in Figure 4 . discussion Different mechanisms underlying a change in biomarkers expression between primary and recurrent BC have been proposed: pre-analytical and analytical errors [22] , intratumoral heterogeneity [23, 24] and selective pressure of previous treatments [25, 26] . Lastly, a switch in tumor biology cannot be excluded: despite breast cancer large-scale genomic original articles Annals of Oncology features seem to remain stable during progression [27] , alterations of individual genes may occur [28] . Since we first reported on discordance between primary and recurrent breast cancer [15] , locoregional/distant relapse biopsy became a common practice at our Institution. The first relevant finding is that this approach might not infrequently results in the diagnosis of a second malignancy, with relevant consequences on patient management. In fact, 14% of the patients were not confirmed as having recurrence from breast cancer, and have received the most appropriate therapy according to the histologic diagnosis.
In our large single-Institution analysis on 119 cases of paired breast cancer primary and confirmed recurrence, the rate of switch to a different tumor phenotype (as defined by different combinations of HR and HER2 expression) was 22.7%, in line with those previous reports adopting a similar definition of the concordant/discordant phenotype [13, 14] . We also evaluated the rates of changes in single-receptor expression, with results of 13.4%, 39% and 11.8% for ER, PgR and HER2, respectively. A recent pooled analysis of two prospective studies including a total of 289 patients reported similar rates of variations. The frequencies of ER loss and PgR loss or gain that we observed are also consistent with that analysis [29] . We confirmed findings from other retrospective and prospective series by identifying PgR as the most discordant receptor, with PgR loss as the main change [11, 15, 17, 20] . Among HER2-discordant cases, more patients gained HER2 expression than those who became HER2 negative, in line with the results of a recent meta-analysis [30] . A large retrospective study including 182 patients with HER2-positive primaries showed a rate of switch to HER2 negative (24%) similar to that we described in the present work [31] .
Our results strongly highlight the prognostic effect of discordance between matched primary breast cancer and recurrence. A change in the tumor phenotype was associated with both significantly shorter PRS and OS. Within the discordant group, a loss of a receptor expression rather than gain resulted as the main determinant of poor prognosis. In fact, patients who changed their tumor phenotype to TN by losing HR and/or HER2 expression experienced the shortest PRS and OS when compared with concordant cases. Moreover, when we evaluated the impact of single-receptor changes, ER loss, HR loss and HER2 loss resulted associated with worse PRS and OS (consistently with previous large retrospective reports [10, 11, 20, 31] ). An adverse prognostic implication of PgR loss has been previously supposed [17, 32] ; however, we did not find a similar correlation in the present study. No association between ER gain, PgR gain, HR gain or HER2 gain and prognosis was observed when compared with the respective concordant negative cases, maybe because all the patients who acquired HER2 positivity or HR positivity at relapse subsequently received adequate targeted treatments.
The available data on the prognostic role of receptor conversion from primary to recurrent breast cancer mainly focused on a single-receptor discordance, with only a few studies reporting on the association between change in tumor phenotype and outcome. However, the results are not always comparable, due to the different definitions of concordance and outcome used in different studies. In a retrospective analysis including 231 matched pairs of breast cancer primaries and recurrences, samples were dichotomized in receptor positive (expressing at least one of the three receptors) and TN. Concordance was defined as either receptor positive or TN phenotype in both primary and recurrence. A significant worse PRS was observed for discordant cases, with the patients changing from receptor positive to TN experiencing the worst prognosis [7] . More recently, a prospective study including 94 patients adopted a more stringent definition of concordance, requiring the same receptor status of each of the three receptors on both paired samples. The primary end point was the proportion of patients in whom results of the metastatic biopsy led to an altered management. No difference in time-to-treatment failure and survival from the date of recurrence biopsy was observed. However, as acknowledged by the author, this study was not powered for survival analyses [17] . Differently from these reports, [17, 33] . In our study, ER and PgR positivity was defined by using the 10% cut-off. The two main reasons for selecting the 10% cut-off are that this is historically the threshold for candidate patients to hormonal therapy, and that recent reports are showing that patients with low ER and/or PgR expression (1-10%) share clinical behavior and gene expression profile with triple-negative breast cancer [34, 35] .
Another main difference with the previous studies by Liedtke et al. and by Amir et al. is the definition of outcome. In our study, we reported an impact on patients' outcome not only from the date of relapse, but also from the date of initial diagnosis. To the best of our knowledge, this is the first study reporting a significant impact of the change of the tumor phenotype and single-receptor discordance from the time of the primary diagnosis.
Our study has other major strengths. All the samples from relapsed tumors were obtained by core-biopsies or surgical resections performed at our Institution, allowing for a complete histological assessment. In some of the previous reports, a proportion of the breast cancer recurrences were sampled by FNA or another cytological technique (48% and 71% of the cases included in the works by Amir and Liedtke, respectively). Cytology samples do not always allow a correct IHC evaluation of prognostic biomarker, when compared with histological specimens [36] . A particular attention to a correct methodology was applied in our work. Indeed, all the specimens from both primaries and recurrences were evaluated at the same laboratory, by the same pathologists and by adopting the same assays, handling procedures and techniques, in order to minimize pre-analytical and analytical errors. Moreover, all the discordant cases were simultaneously restained. Nevertheless, some weakness has to be underlined. This is a retrospective study with the potential bias of enriching for cases with unusual clinical course. Moreover, recurrent tumor biopsies were not always collected at the time of the diagnosis of recurrent disease, allowing for potential additional effects of treatment administered for the metastatic disease on receptor expression. Finally, given the relatively small number of cases, it was not possible to consider interactions between biological changes and features concerning clinical presentation of relapsed tumors, such as disease burden. Therefore, on the basis of our data, we cannot conclude that discordance has an independent prognostic value; further research is needed.
In conclusion, discordance in receptor expression between primary and recurrent breast cancer has been confirmed in this single-Institution analysis, by adopting standardized assays and procedures. We reported for the first time a significant worse prognostic impact of phenotype discordance in terms of OS, mainly driven by those patients who lost some receptor expression. The poorer outcome observed for patients with the receptor loss may be due to the selection of resistant clones as a consequence of previous treatments, or to a biologic switch to a more aggressive phenotype. It is, however, important to underline that, at present, there are no data supporting the withdrawal of a targeted drug if the target is not expressed at relapse; on the contrary, a gain in HR or HER2 expression would allow to offer the patients new treatment options. In this analysis, all the patients who gained a receptor expression were treated with targeted agents according to the new phenotype and experienced a similar outcome when compared with the concordant receptor-negative cases. Future studies are needed in order to investigate whether a tight adherence to therapeutic strategies based on the biomarker profile of the recurrent disease might improve patient prognosis.
Nowadays, we acknowledge that the receptor loss accounts for the majority of the discordance, thus identifying those patients at worse outcome without the possibility of offering alternative effective treatments. However, the aim of personalized or precision medicine is to customize treatments on the basis of the molecular and genomic features of each individual tumor [37, 38] . In this perspective, the characterization of relapsing breast cancer can play a major role.
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